Propulsid – Page 2 – Alliance for Human Research Protection

October 26, 2006

Linguistic Tinkering with Regulatory Terminology Increases Risk of Harm for Children

Linguistic Tinkering with Regulatory Terminology Increases Risk of Harm for Children: "minimal risk" "minor increment of minimal

Linguistic Tinkering with Regulatory Terminology Increases Risk of Harm for Children

October 26, 2006

AHRP Files Court Brief to Protect Children from Harmful Research

October 1, 2001 Text of AHRP Amicus Brief filed with the Maryland Court of Appeals in support

AHRP Files Court Brief to Protect Children from Harmful Research

October 26, 2006

FDA: Regulatory Protections for Children. Comments by Sharav, Noble, & Fishman for AHRP

FDA: regulatory protections for children. Comments submitted by Vera Hassner Sharav, John H. Noble, Jr., Ph.D and

FDA: Regulatory Protections for Children. Comments by Sharav, Noble, & Fishman for AHRP

October 26, 2006

Dissenting Opinion: Against waiving parental permission for research

Dissenting Opinion: Against Waiving Parental Permission for Research July 25, 2001 To: Mary Faith Marshall, Ph.D, Chairperson,

Dissenting Opinion: Against waiving parental permission for research

October 26, 2006

The Impact of the FDA Modernization Act on the Recruitment of Children for Research

THE IMPACT OF THE FDA MODERNIZATION ACT ON THE RECRUITMENT OF CHILDREN FOR RESEARCH Vera Hassner Sharav

The Impact of the FDA Modernization Act on the Recruitment of Children for Research

January 14, 2006

S. Finance Committee Investigates Drug Makers Over Medical Education Grants_NYT

Such payments are, in fact, kick backs for these groups’ promotional services encouraging doctors to prescribe drugs

S. Finance Committee Investigates Drug Makers Over Medical Education Grants_NYT

September 12, 2005

Abbott Seeks FDA approval for cancer drug despite failed trials – WSJ

Abbott Seeks FDA approval for cancer drug despite failed trials – WSJ Mon, 12 Sep 2005 Abbott

Abbott Seeks FDA approval for cancer drug despite failed trials – WSJ

July 18, 2005

2005: “Cheaper than Chimpanzees” by Vera Sharav

THE ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) www.ahrp.org CHEAPER THAN CHIMPANZEES Statement Presented By VERA HASSNER SHARAV

2005: “Cheaper than Chimpanzees” by Vera Sharav

June 10, 2005

Lucrative Drug, Danger Signals and the F.D.A. – NY Times

http://www.nytimes.com/2005/06/10/business/10drug.html?ei=5094&en=5475b3c17e50e692&hp =&ex=1118462400&partner=homepage&pagewanted=print THE NEW YORK TIMES June 10, 2005, front page Lucrative Drug, Danger Signals and the

Lucrative Drug, Danger Signals and the F.D.A. – NY Times

August 18, 2003

Best Pharmaceuticals for Children Act of 2002

Comments submitted by The Alliance for Human Research Protection The National Academy of Sciences Committee of the

Best Pharmaceuticals for Children Act of 2002

January 15, 2003

References: Impact of FDA inclusion of children as test subjects

References for THE IMPACT OF THE FDA MODERNIZATION ACT ON THE RECRUITMENT OF CHILDREN FOR RESEARCH Vera

References: Impact of FDA inclusion of children as test subjects

May 14, 2002

Dissenting Opinion – Proposed Children’s Workgroup Reinterpretation of Fed Regs 45 CFR 46 sects. 404 & 406

Dissenting Opinion (NHRPAC Children Workgroup) re: Proposed Reinterpretation of Fed. Regs Protecting Children (45 CFR 46, sections

Dissenting Opinion – Proposed Children’s Workgroup Reinterpretation of Fed Regs 45 CFR 46 sects. 404 & 406

May 7, 2002

Conflicts of Interest in Clinical Trials

Presented by Vera Hassner Sharav 14th Tri-Service Clinical Investigation Symposium Sponsored by The U.S. Army Medical Department

Conflicts of Interest in Clinical Trials

May 5, 2002

Sharav Presentation before US Army Medical Dept., May 6, 2002

CONFLICTS OF INTEREST Presented by Vera Hassner Sharav 14th TRI-SERVICE CLINICAL INVESTIGATION SYMPOSIUM Sponsored By THE U.S.

Sharav Presentation before US Army Medical Dept., May 6, 2002

Load More Articles

Subscribe to Our Newsletter!